Currently Viewing:
AMCP 2017
Dr Jennifer Graff on How Payers Make Decisions
August 01, 2017
Laura Topor Discusses Challenges of e-Prescribing Specialty Medications
July 11, 2017
Dr Jacqueline Glover: Financial Knowledge Is Part of Informed Consent
July 10, 2017
Laura Topor Explains the Value of Real-Time Benefit Transactions
June 27, 2017
Dr Jacqueline Glover: Clinicians' Obligations of Justice Regarding Costs of Care
June 24, 2017
Dr Lou Garrison Discusses Challenges of Working With Real-World Data
June 16, 2017
Dr Neil Minkoff Explains How 340B Impacts Pharmacies and Payers Differently
June 15, 2017
Dr Matthew Pickering on Working With Health Plans on Measure Implementation
June 09, 2017
Laura Topor: Clearing Up Misconceptions About e-Prescribing
June 07, 2017
Dr Jacqueline Glover Discusses the Complicated Balance of Ethics in Drug Trials
June 05, 2017
Dr Richard J. Willke Discusses Challenges of Working With Real-World Data
June 02, 2017
Susan A. Cantrell Explains the Necessity of Pre- and Post-Approval Communications
May 31, 2017
Dr Neil Minkoff Discusses Evolution and Consequences of 340B Programs
May 30, 2017
Dr Doug Hillblom Discusses Legislative Pushes Toward e-Prescribing
May 25, 2017
Dr Matthew Pickering Describes Challenges of New Measure Implementation
May 24, 2017
Dr Aimee Tharaldson Discusses the Orphan Drug Approval Trend
May 22, 2017
Currently Reading
Dr Gail Bridges on the Importance of Real-World Results Matching Clinical Trial Outcomes
May 21, 2017
Dr Richard J. Willke on the Value of Real-World Data for Health Plans
May 18, 2017
Dr Lou Garrison on the Discussions Surrounding Outcomes-Based Arrangements
May 17, 2017

Dr Gail Bridges on the Importance of Real-World Results Matching Clinical Trial Outcomes

With the high cost of new drugs to cure hepatitis C, ensuring that real-world outcomes are consistent with those seen in clinical trials is important, explained Gail Bridges, PharmD, of Accredo Health. She explained that Accredo ensured patients adhered to hepatitis C drugs in order to get the best outcomes through a disease- and drug-specific education program.


With the high cost of new drugs to cure hepatitis C, ensuring that real-world outcomes are consistent with those seen in clinical trials is important, explained Gail Bridges, PharmD, of Accredo Health. She explained that Accredo ensured patients adhered to hepatitis C drugs in order to get the best outcomes through a disease- and drug-specific education program.

Transcript

What impact do you think drug-specific education had on patients taking Harvoni or Viekira Pak for hepatitis C? Is the model translatable to other disease states?

As we're all aware, adherence is challenging in the real world. In our experience I think it takes an array of support tools to really help patients succeed on these therapies. In our study patients received care from specialty pharmacists and nurses who focused solely on hepatitis C.

So they received drug- and disease-specific education, as well as access to technology support, such as the Accredo Plus C adherence app, videos, they received proactive adherence coaching throughout their therapy. So all of these things contributed to, I think, the results that we saw in this study [that cure rates in the real-world were similar to those in clinical trials for patients taking Viekira Pak and Harvoni for hepatitis C].

I don't think there's one solution for all patients, but I think having a robust toolkit of these support methodologies, if you will, is important, so taht each patient can find the right tool that works for them.

With the high cost of hepatitis C drugs, what is the importance of determining the real-world outcomes and the fact that they are similar to clinical trial results?

We all are stewards of our healthcare resources, right? So we all have a role to play in ensuring judicious use of those resources. And any time there's such a large increase in cost, as we saw with the advent of the direct-acting antiviral era, we have to examine those real-world outcomes and make sure that those benefits are commensurate to that cost increase.

Historically, we've struggled a little bit in hepatitis C to really achieve real-world results that are on point with those seenn in clinical trials. So I think that it's exciting to see that we have data now to show that our patients, taking these medications in the specialty model can achieve those types of results that are consistent with those seen in clinical trials.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!